Anavex Life Sciences Corp. (AVXL)
Stock Price:
$4.80 USD
0.38 (8.60%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
After-hours: $4.85 +0.05 (1.04%) Aug 4, 7:58 PM
Key Info
| Market Cap |
288.40M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-24.78M |
| Shares Out |
60.08M |
| EPS (ttm) |
-0.48 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$4.80 |
| Previous Close |
$4.42 |
| Change ($) |
0.38 |
| Change (%) |
8.60% |
| Day's Open |
4.39 |
| Day's Range |
4.36 - 4.88 |
| Day's Volume |
555,197 |
| 52-Week Range |
2.20 - 6.31 |
More Stats
| Market Cap |
288.40M |
| Enterprise Value |
261.83M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
60.08M |
| Float |
56.37M |
| EPS (basic) |
-0.45 |
| EPS (diluted) |
-0.48 |
| FCF / Share |
-0.36 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
6.39M |
| Short Ratio |
6.94 |
| Short % of Float |
11.95% |
| Beta |
1.51 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
10.83 |
| Revenue |
n/a |
| Operating Income |
-28.97M |
| Net Income |
-24.78M |
| Free Cash Flow |
-21.02M |
| Net Cash |
26.56M |
| Net Cash / Share |
0.44 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-63.06% |
| ROE |
-133.21% |
| ROIC |
1,127.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$12.00*
(150.00% upside)
Low
8.00
Current: $4.80
High
16.00
Target: 12.00
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -29.11 | -19.33 | -15.68 | -15.59 | -7.11 | -2.97 | -2.14 | -4.32 | -6.17 | -5.64 |
| Net Income | -26.29 | -17.25 | -13.46 | -14.74 | -12.11 | -9.97 | -3.70 | -8.30 | -7.31 | -8.78 |
| Shares Outstanding | 48.91 | 44.66 | 40.84 | 35.15 | 18.58 | 9.80 | 7.98 | 7.04 | 6.29 | 5.36 |
| Earnings Per Share | -0.54 | -0.39 | -0.33 | -0.42 | -0.65 | -1.02 | -0.48 | -1.16 | -1.16 | -1.64 |
| Operating Cash Flow | -18.53 | -12.58 | -9.02 | -9.24 | -4.23 | -2.66 | -0.78 | -1.69 | -3.80 | -4.59 |
| Capital Expenditures | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -18.53 | -12.58 | -9.02 | -9.24 | -4.23 | -2.66 | -0.78 | -1.69 | -3.80 | -4.60 |
| Cash & Equivalents | 22.19 | 22.98 | 27.49 | 9.24 | 15.29 | 7.26 | 0.35 | 0.01 | 0.13 | 0.26 |
| Total Debt | - | - | - | - | 0.09 | 0.19 | 0.21 | 0.30 | 0.87 | 2.49 |
| Net Cash / Debt | 22.19 | 22.98 | 27.49 | 9.24 | 15.21 | 7.07 | 0.13 | -0.29 | -0.73 | -2.23 |
| Assets | 25.33 | 26.21 | 27.84 | 9.50 | 15.47 | 7.35 | 0.39 | 0.01 | 0.20 | 0.33 |
| Liabilities | 5.04 | 3.88 | 3.58 | 3.19 | 2.66 | 7.16 | 2.86 | 2.89 | 1.35 | 3.29 |
| Book Value | 20.29 | 22.32 | 24.25 | 6.31 | 12.81 | 0.19 | -2.46 | -2.88 | -1.14 | -2.96 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Anavex Life Sciences Corp. |
| Country |
United States |
| Employees |
16 |
| CEO |
Christopher U. Missling |
Stock Information
| Ticker Symbol |
AVXL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: AVXL |
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase II clinical trials to treat Parkinson's disease; and preclinical clinical trials to treat Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Its preclinical drug candidates include ANAVEX 3-71, a central nervous system (CNS)-penetrable mono-therapy to treat Alzheimer's and Parkinson's diseases; ANAVEX 1-41, a sigma-1 agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.